A familial Alzheimer's genetic panel sequences three genes — PSEN1, APP and PSEN2 — and tells you whether you carry a pathogenic variant that causes autosomal-dominant Alzheimer's disease. That is all it measures.
It does not detect Alzheimer's pathology in your brain, it does not cover other dementia genes, and it does not tell you when symptoms would begin. Running one before a memory clinic visit answers a narrow inherited-risk question while leaving the clinic's actual job untouched. Understanding the gap ahead of time keeps you from walking in with a result you think is an answer, and walking out learning it was a footnote.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What the three-gene panel actually sequences
- Does this panel apply to you at all?
- A positive result does not come with a date
- APOE is a different test with different rules
- What the clinic visit does that no panel can
- The insurance exposure people miss
- Frequently Asked Questions
What the three-gene panel actually sequences
Autosomal-dominant familial Alzheimer's — the form passed directly from parent to child, where one copy of the variant is enough to cause disease — traces to pathogenic variants in three genes. According to ARUP Laboratories' early-onset Alzheimer panel documentation, PSEN1 accounts for roughly 20–70% of familial early-onset cases, APP for 10–15%, and PSEN2 for about 5%. Those three genes are the entire content of a standard familial panel. The sequencing covers the coding regions and the intron–exon boundaries of those genes.
ARUP notes that deep intronic variants and regulatory changes fall outside detection, as do genes behind frontotemporal lobar degeneration, Lewy body disease and vascular dementia. A panel that returns "no pathogenic variant found" has ruled out one specific mechanism, not inherited dementia. Yield matters here. Even in families selected for early-onset disease, ARUP reports the panel identifies a causative variant in only about 60–80% of cases, and the rate falls as age of onset rises. A negative result in a family with a strong history is a common outcome, not a reassuring one.
Does this panel apply to you at all?
For most people arriving at a memory clinic, it does not. Early-onset Alzheimer's with dominant inheritance accounts for roughly 1–2% of all Alzheimer's diagnoses, according to a 2012 review by Guerreiro and colleagues with National Institute on Aging affiliation.
The panel addresses a small minority of patients. The family patterns that make the panel worth considering look distinctive: A single affected parent who developed memory problems in their 80s does not fit this pattern. Late-onset Alzheimer's clusters in families through common risk variants and shared environment, not through a single dominant gene the panel can find.
- Symptoms starting before 65, and often in the 40s or 50s
- An affected parent, plus affected grandparents or siblings — disease in every generation
- Roughly half of siblings affected, rather than one isolated case
- A known pathogenic variant already identified in a relative
A positive result does not come with a date
Carriers often want the panel to tell them when. It does not. Penetrance — whether and when a variant produces symptoms — varies within a single family carrying a single variant. A study published in Alzheimer's Research & Therapy in May 2018 followed a family carrying the PSEN1 H163Y variant for 22 years. Mean symptom onset was 51 years, give or take 7.
Yet one carrier in that family remained symptom-free at 65 — fourteen years past the family mean. The authors attribute the spread to genetic, epigenetic and environmental modifiers. That finding cuts both ways for planning. A carrier cannot assume safety from passing a family's average age, and cannot treat that average as a deadline either. The result establishes that a variant is present; the timeline stays open.
APOE is a different test with different rules
Most people who have consumer genetic data have APOE results, not PSEN1 or APP results — and the two are not interchangeable. APOE ε4 is a risk factor, not a cause. Carrying it raises the odds; it does not determine the outcome, and it will not appear on a familial panel. The clinical guidance has been cautious.
The 2011 joint ACMG/NSGC document recommends against clinical APOE testing, and in a 2019 addendum the American College of Medical Genetics and Genomics downgraded that document to a Practice Resource rather than an evidence-based guideline. APOE has nonetheless acquired one concrete use the familial panel lacks. The FDA prescribing information for lecanemab (Leqembi), in its 2025 label revision, directs prescribers to test ApoE ε4 status before treatment. The reason is safety: ε4 homozygotes, about 15% of Alzheimer's patients, have higher rates of symptomatic, serious and severe ARIA — amyloid-related imaging abnormalities, the brain swelling and bleeding seen on MRI during anti-amyloid therapy. If a treatment decision is on the table, APOE status matters in a way a three-gene panel does not.
What the clinic visit does that no panel can
A gene panel measures no Alzheimer's pathology. Blood-based pathology testing is now a separate option: on May 16, 2025, the FDA cleared the first blood test for diagnosing Alzheimer's disease, Fujirebio's Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio, for symptomatic adults 55 and older — with results required to be interpreted alongside other clinical information. The visit itself supplies that clinical information. The 2024 Alzheimer's Association DETeCD-ADRD guideline, built from a review of 7,374 publications with 133 included, sets out a three-step formulation: establish the level of impairment, then the cognitive-behavioral syndrome, then the likely underlying brain disease.
Genotype feeds into the third step at most. The guideline explicitly excludes people without symptoms from its scope. So the sequence that works is clinic first, panel second, if the clinician thinks the family pattern warrants it. A panel ordered ahead of the visit changes nothing about the evaluation and may answer a question nobody was going to ask.
The insurance exposure people miss
Testing before a clinic visit often means testing outside a clinician's order, and that carries a financial consequence worth knowing in advance. The Genetic Information Nondiscrimination Act covers health insurance and employment only. As MedlinePlus Genetics at the National Library of Medicine explains, life, disability and long-term care insurers remain free to use a positive genetic result unless a state law says otherwise.
That ordering problem is concrete. Long-term care coverage is exactly the product a person worried about familial Alzheimer's is most likely to want, and a positive PSEN1 result on record can affect eligibility or pricing for it. Several states restrict this; most do not. The practical step is to settle insurance arrangements before testing, not after — and to raise the question with a genetic counselor rather than a test vendor's support line, since the vendor has no stake in what the result costs you later.
Frequently Asked Questions
My direct-to-consumer test reported APOE ε4. Should I get the familial panel too?
The familial panel tests different genes and would not confirm or refine an APOE result. Early-onset dominant Alzheimer's accounts for only about 1–2% of diagnoses, so the panel is worth discussing only if your family shows early onset across generations.
Will a negative familial panel rule out inherited dementia?
No. ARUP Laboratories reports the panel finds a causative variant in only about 60–80% of selected early-onset families, and it does not cover deep intronic variants, regulatory regions, or the genes behind frontotemporal, Lewy body and vascular disease.
Can the panel tell a carrier how long they have before symptoms?
No. In the PSEN1 H163Y family followed for 22 years, mean onset was 51 ± 7 years, yet one carrier was still symptom-free at 65.
